121 related articles for article (PubMed ID: 38258851)
1. High Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among Urban Syringe Service Program Participants.
Fox AD; Riback L; Perez-Correa A; Ohlendorf E; Ghiroli M; Behrends CN; López-Castro T
Subst Use Addctn J; 2024 Jan; 45(1):44-53. PubMed ID: 38258851
[TBL] [Abstract][Full Text] [Related]
2. Treatment History and Interest in Injectable Opioid Agonist Treatment With Hydromorphone Among People Who Inject Drugs.
Ohlendorf E; Perez-Correa A; Riback L; Ghiroli M; Lopez-Castro T; Fox AD
J Addict Med; 2023 May-Jun 01; 17(3):e148-e155. PubMed ID: 37267166
[TBL] [Abstract][Full Text] [Related]
3. Patterns of use and adverse events reported among persons who regularly inject buprenorphine: a systematic review.
Bozinoff N; Tardelli VS; Rubin-Kahana DS; Le Foll B
Harm Reduct J; 2022 Oct; 19(1):113. PubMed ID: 36229831
[TBL] [Abstract][Full Text] [Related]
4. Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities.
Nielsen S; Sanfilippo P; Belackova V; Day C; Silins E; Lintzeris N; Bruno R; Grebely J; Lancaster K; Ali R; Bell J; Dietze P; Degenhardt L; Farrell M; Larance B
Addiction; 2021 Jun; 116(6):1482-1494. PubMed ID: 33067836
[TBL] [Abstract][Full Text] [Related]
5. Injecting Alone: Practices and Preferences among People Who Inject Drugs in New York City.
Riback L; Pérez-Correa AE; Ghiroli MM; López-Castro T; Fox AD
Subst Use Misuse; 2022; 57(13):1988-1996. PubMed ID: 36151968
[TBL] [Abstract][Full Text] [Related]
6. Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling).
Dobischok S; Metcalfe R; Matzinger E; Palis H; Marchand K; Harrison S; MacDonald S; Byres D; Schechter M; Bansback N; Oviedo-Joekes E
Int J Drug Policy; 2023 Feb; 112():103948. PubMed ID: 36586152
[TBL] [Abstract][Full Text] [Related]
7. Hospital Initiated Injectable Opioid Agonist Therapy for the Treatment of Severe Opioid Use Disorder: A Case Series.
Brar R; Fairbairn N; Colizza K; Ryan A; Nolan S
J Addict Med; 2021 Apr; 15(2):163-166. PubMed ID: 32769776
[TBL] [Abstract][Full Text] [Related]
8. Perinatal Injectable Opioid Agonist Therapy (iOAT) Administration: A Case Series.
Patricelli CJ; Chai J; Gordon S; Gouin IJ; Carter N; Stewart K; Paquette V; Urbanoski K; Albert A
J Addict Med; 2023 Jul-Aug 01; 17(4):431-438. PubMed ID: 37579103
[TBL] [Abstract][Full Text] [Related]
9. Injectable opioid agonist treatment: An evolutionary concept analysis.
Haines M; O'Byrne P
Res Nurs Health; 2021 Aug; 44(4):664-671. PubMed ID: 33993526
[TBL] [Abstract][Full Text] [Related]
10. Prescription opioid injection among young people who inject drugs in New York City: a mixed-methods description and associations with hepatitis C virus infection and overdose.
Mateu-Gelabert P; Guarino H; Zibbell JE; Teubl J; Fong C; Goodbody E; Edlin B; Salvati C; Friedman SR
Harm Reduct J; 2020 Mar; 17(1):22. PubMed ID: 32228700
[TBL] [Abstract][Full Text] [Related]
11. Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.
Geddes L; Iversen J; Wand H; Maher L
Addiction; 2021 Mar; 116(3):525-535. PubMed ID: 32557931
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Sivakumar A; Madden L; DiDomizio E; Eller A; Villanueva M; Altice FL
Int J Drug Policy; 2022 Mar; 101():103570. PubMed ID: 34954493
[TBL] [Abstract][Full Text] [Related]
13. Interest in long-acting injectable buprenorphine among syringe services program participants.
Epstein H; Perez-Correa A; Beltre J; Fitzsimmons C; Marcus P; Ramirez F; Stern LS; Norton BL; Fox AD; Jakubowski A
J Opioid Manag; 2021; 17(7):59-67. PubMed ID: 34520027
[TBL] [Abstract][Full Text] [Related]
14. Utilization of buprenorphine and methadone among opioid users who inject drugs.
Tsui JI; Burt R; Thiede H; Glick SN
Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
[TBL] [Abstract][Full Text] [Related]
15. Can Treatment for Substance Use Disorder Prescribe the same Substance as that Used? The Case of Injectable Opioid Agonist Treatment.
Steel D; Tekin Ş
Kennedy Inst Ethics J; 2021; 31(3):271-301. PubMed ID: 34565745
[TBL] [Abstract][Full Text] [Related]
16. Modeling the cost and impact of injectable opioid agonist therapy on overdose and overdose deaths.
Tse WC; Scott N; Dietze P; Nielsen S
J Subst Abuse Treat; 2022 Dec; 143():108871. PubMed ID: 36182753
[TBL] [Abstract][Full Text] [Related]
17. Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment.
Marchand K; Foreman J; MacDonald S; Harrison S; Schechter MT; Oviedo-Joekes E
Subst Abuse Treat Prev Policy; 2020 Jan; 15(1):7. PubMed ID: 31959189
[TBL] [Abstract][Full Text] [Related]
18. HIV Treatment Initiation and Retention Among Individuals Initiated on Injectable Opioid Agonist Therapy for Severe Opioid Use Disorder: A Case Series.
Giang V; Brar R; Sutherland C; Nolan S
J Addict Med; 2020; 14(5):437-440. PubMed ID: 32011407
[TBL] [Abstract][Full Text] [Related]
19. Understanding the public health consequences of suspending a rural syringe services program: a qualitative study of the experiences of people who inject drugs.
Allen ST; Grieb SM; O'Rourke A; Yoder R; Planchet E; White RH; Sherman SG
Harm Reduct J; 2019 May; 16(1):33. PubMed ID: 31109339
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Ottawa, Canada's Managed Opioid Program (MOP) where supervised injectable hydromorphone was paired with assisted housing.
Harris MT; Seliga RK; Fairbairn N; Nolan S; Walley AY; Weinstein ZM; Turnbull J
Int J Drug Policy; 2021 Dec; 98():103400. PubMed ID: 34469781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
